RAD51 inhibitor compounds are a specialized class of small-molecule therapeutics designed to target the RAD51 protein, a key mediator of the homologous recombination DNA repair pathway. By disrupting this… Read more
RAD51 inhibitor compounds are a specialized class of small-molecule therapeutics designed to target the RAD51 protein, a key mediator of the homologous recombination DNA repair pathway. By disrupting this mechanism, these agents induce genomic instability and cell death in rapidly dividing cells, offering potential applications for treating cancers that rely on efficient DNA repair, such as those with BRCA mutations. This category features the parent RAD51 inhibitor and its corresponding stable isotope labelled analog, which function as essential reference standards in pharmaceutical laboratories. Researchers and analytical chemists utilize these high-quality materials for precise method validation, impurity profiling, and robust quality control procedures. Furthermore, the inclusion of labelled compounds is critical for accurate quantification and pharmacokinetic studies, ensuring reliable data during drug development and analytical testing workflows.